Avid Bioservices creates technology and transformation role amid strategic expansion
US contract development and manufacturing organization Avid Bioservices (Nasdaq: CDMO) has appointed Dave Stewart as chief technology and transformation officer, a newly created position that signals the company’s next growth phase under chief executive Kenneth Bilenberg.
The move follows Avid’s plan to strengthen its digital modernization, automation, and advanced manufacturing systems across its biologics network. The company aims to improve efficiency, integration, and flexibility as it prepares for further expansion and future ownership under private-equity control.
Mr Stewart will oversee technology integration and process transformation initiatives spanning Avid’s development and manufacturing sites, aligning systems and platforms with broader business goals. His appointment reflects Avid’s focus on long-term transformation, emphasizing the company’s ambition to remain a reliable and agile CDMO partner to clients worldwide.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze